BRPI0621181A8 - Substâncias imunogênicas que compreendem um adjuvante a base de ácido poliinosínico - ácido policitidílico - Google Patents

Substâncias imunogênicas que compreendem um adjuvante a base de ácido poliinosínico - ácido policitidílico

Info

Publication number
BRPI0621181A8
BRPI0621181A8 BRPI0621181A BRPI0621181A BRPI0621181A8 BR PI0621181 A8 BRPI0621181 A8 BR PI0621181A8 BR PI0621181 A BRPI0621181 A BR PI0621181A BR PI0621181 A BRPI0621181 A BR PI0621181A BR PI0621181 A8 BRPI0621181 A8 BR PI0621181A8
Authority
BR
Brazil
Prior art keywords
acid
immune response
adjuvant
immunogenic
polycytydylic
Prior art date
Application number
BRPI0621181A
Other languages
English (en)
Inventor
Lin Haixiang
Lie Tao Li Victor
Original Assignee
Newbiomed Pika Pte Ltd
Yisheng Biopharma Singapore Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newbiomed Pika Pte Ltd, Yisheng Biopharma Singapore Pte Ltd filed Critical Newbiomed Pika Pte Ltd
Publication of BRPI0621181A2 publication Critical patent/BRPI0621181A2/pt
Publication of BRPI0621181A8 publication Critical patent/BRPI0621181A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SUBSTÂNCIAS IMUNOGÊNICAS QUE COMPREENDEM UM ADJUVANTE A BASE DE ÁCIDO POLIINOSÍNICO - ÁCIDO POLICITIDÍLICO, onde é prevista uma composição de adjuvante polinucleotídico (PICKCa) e métodos de uso para provocar uma resposta imunológica, em particular uma resposta imunológica da mucosa, sendo que o adjuvante polinucleotídico compreende um ácido polirriboinosínico-polirribocitidílico (PJC), pelo menos um antibiótico e pelo menos um íon positivo; prevendo-se também uma composição imunogênica que compreende a composição de adjuvante polinucleotídico com outras composições imunogénicas como um antígeno (por ex., como em uma vacina) selecionadas de antígenos virais, bacterianos, fúngicos, parasíticos e/ou de câncer; e, ainda, contempla métodos de uso de tais composições adjuvantes, particularmente para provocar uma resposta imunológica, em especial uma resposta imunológica da mucosa a um composto antigênico.
BRPI0621181A 2006-01-13 2006-06-27 Substâncias imunogênicas que compreendem um adjuvante a base de ácido poliinosínico - ácido policitidílico BRPI0621181A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/331,575 US20070166800A1 (en) 2006-01-13 2006-01-13 Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
US11/331,575 2006-01-13
PCT/SG2006/000176 WO2007081287A1 (en) 2006-01-13 2006-06-27 Immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant

Publications (2)

Publication Number Publication Date
BRPI0621181A2 BRPI0621181A2 (pt) 2011-11-22
BRPI0621181A8 true BRPI0621181A8 (pt) 2017-09-12

Family

ID=38256597

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0621181A BRPI0621181A8 (pt) 2006-01-13 2006-06-27 Substâncias imunogênicas que compreendem um adjuvante a base de ácido poliinosínico - ácido policitidílico

Country Status (16)

Country Link
US (4) US20070166800A1 (pt)
EP (1) EP1971402A4 (pt)
JP (1) JP2009523721A (pt)
KR (1) KR20080091106A (pt)
CN (1) CN101166559B (pt)
AU (1) AU2006335367B2 (pt)
BR (1) BRPI0621181A8 (pt)
CA (1) CA2632415A1 (pt)
CU (1) CU23810A3 (pt)
IL (1) IL192746A0 (pt)
MY (1) MY150706A (pt)
NZ (1) NZ570379A (pt)
RU (1) RU2462264C2 (pt)
TW (1) TWI503125B (pt)
WO (1) WO2007081287A1 (pt)
ZA (1) ZA200806339B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101203401B1 (ko) * 2005-06-08 2012-11-22 이쉥 바이오파마(싱가포르)피티이 리미티드 폴리이노신산-폴리시티딜산-기초 보조제
US20070166239A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant
US20070166800A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
NZ587371A (en) * 2008-02-15 2012-12-21 Hemispherx Biopharma Inc The use of poly(I:C11-14U) for treating bacterial and protozoan infection
RU2441667C1 (ru) * 2010-12-09 2012-02-10 Иосиф Григорьевич Атабеков Новый тип частиц-носителей (платформ) для получения активных комплексов
RU2440140C1 (ru) * 2010-12-09 2012-01-20 Иосиф Григорьевич Атабеков Иммуногенная композиция, содержащая чужеродные антигены на поверхности сферических носителей, полученных при термической денатурации спиральных вирусов
US9303068B2 (en) 2012-11-30 2016-04-05 The Regents Of The University Of California D-amino acid derivative-modified peptidoglycan and methods of use thereof
SI3542819T1 (sl) * 2013-05-14 2021-11-30 Zoetis Services Llc Sestave novih cepiv, ki vsebujejo imunostimulatorne oligonukleotide
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
WO2016105274A1 (en) * 2014-12-23 2016-06-30 Yisheng Biopharma (Singapore) Pte Ltd A rabies composition comprising pika adjuvant
US9913800B2 (en) * 2015-04-28 2018-03-13 The Procter & Gamble Company Compositions and methods for improving skin health
CN105396130A (zh) * 2015-11-10 2016-03-16 林海祥 皮氨钙佐剂及含有皮氨钙佐剂的疫苗
PT3319587T (pt) * 2015-11-17 2019-11-20 Bioncotech Therapeutics S L Nova composição farmacêutica que compreende partículas compreendendo um complexo de um polirribonuleótido de cadeia dupla e uma polialquilenoimina
CN106075431A (zh) * 2016-03-23 2016-11-09 林海祥 皮氨钙联合佐剂及含有皮氨钙联合佐剂的疫苗
CN107198777A (zh) * 2016-04-01 2017-09-26 依生生物制药(新加坡)私人有限公司 用于治疗癌症的含有聚核苷酸的药物组合物
CN106075432A (zh) * 2016-04-27 2016-11-09 林海祥 皮卡钙联合佐剂及含有皮卡钙联合佐剂的疫苗
CN107875168B (zh) * 2016-09-30 2022-03-04 广州百吉生物制药有限公司 一种免疫调节组合物在治疗恶性积液中的用途
JP2020520368A (ja) * 2017-05-17 2020-07-09 ビオンコテック セラピューティクス エセ．エレ 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物
CN109125264B (zh) 2017-06-19 2020-10-30 林海祥 一种抗感染抗肿瘤的粘膜免疫制剂
US11135286B2 (en) 2017-08-10 2021-10-05 Yisheng Biopharma (Singapore) Pte Ltd Composition for treating and/or preventing Hepatitis B virus infection and the use thereof
CN109078180B (zh) * 2018-06-29 2019-05-31 信福(北京)医药科技有限公司 用于增强免疫响应的复合物
JP7296644B2 (ja) * 2018-06-29 2023-06-23 信福（北京）医▲薬▼科技有限公司 免疫応答を強化するための複合物の調製方法
CN109663126A (zh) * 2019-03-01 2019-04-23 龙阔（苏州）生物工程有限公司 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗
AU2021278137A1 (en) * 2020-05-29 2023-01-05 Beijing Yisheng Biotechnology Co., Ltd. Pharmaceutical composition comprising polynucleotides and use thereof for prevention or treatment of COVID-19
WO2021243248A2 (en) * 2020-05-29 2021-12-02 Children's Medical Center Corporation Adjuvants for severe acute respiratory syndrome-related coronavirus (sars-cov) vaccines
WO2024102079A1 (en) * 2022-11-09 2024-05-16 Zeno Therapeutics Pte Ltd Compositions comprising polyinosinic-polycytidylic acid, epstein-barr (ebv) virus-like particles and ebv-specific car-t cells for improving immune cell therapy

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692899A (en) * 1969-12-17 1972-09-19 Us Health Education & Welfare Inhibition of transplanted tumor growth by polyinosinic-polycytidylic acid in mice
US3666646A (en) * 1970-05-15 1972-05-30 Merck & Co Inc Reduction of molecular weight in polynucleotides using ultrasonic radiation
US4124702A (en) * 1971-07-06 1978-11-07 Merck & Co., Inc. Polynucleotides active as inducers of interferon production in living animal cells
US3906092A (en) * 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
US4186194A (en) * 1973-10-23 1980-01-29 Agence Nationale De Valorisation De La Recherche (Anvar) Water soluble agents effective as immunological adjuvants for stimulating, in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
US3952097A (en) * 1974-09-27 1976-04-20 The United States Of America As Represented By The Department Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US4024241A (en) * 1974-09-27 1977-05-17 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
FR2321896A1 (fr) * 1975-08-29 1977-03-25 Anvar Agents adjuvants immunologiques actifs en solution aqueuse
US4153684A (en) * 1976-03-10 1979-05-08 Agence Nationale De Valorisation De La Recherche (Anvar) Immunizing and anti-infectious adjuvant agents constituted by N-acetyl-muramyl-L-alanyl-D-glutamic acid derivatives
US4082735A (en) * 1976-04-26 1978-04-04 Syntex (U.S.A.) Inc. Novel immunological adjuvant compounds and methods of preparation thereof
US4082736A (en) * 1976-04-26 1978-04-04 Syntex (U.S.A.) Inc. Novel immunological adjuvant compounds and methods of preparation thereof
GB1563561A (en) * 1976-06-23 1980-03-26 Daiichi Seiyaku Co Muramyldipeptide derivatives and process for the preparation thereof
FR2368282A1 (fr) * 1976-10-22 1978-05-19 Anvar Adjuvant immunologique constitue par le p-amino-phenyl de n-acetyl-muramyl-l-alanyl-d-isoglutamine
US4140761A (en) * 1977-04-11 1979-02-20 The United States Of America As Represented By The Department Of Health, Education & Welfare Modification of hepatitis B virus infection in chronic carriers of hepatitis B surface antigen
JPS55111499A (en) * 1979-02-21 1980-08-28 Takeda Chem Ind Ltd Glucosamine derivative and its preparation
CA1185237A (en) * 1979-02-28 1985-04-09 Yuichi Yamamura 6-deoxyglucosamine-peptide derivatives, their production and use
NZ194880A (en) 1979-09-17 1983-07-15 Merck & Co Inc Interferon-inducing composition containing modified polyriboinosinic-polyribocytidylic acid
US4349538A (en) * 1979-12-07 1982-09-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
FR2476488A2 (fr) 1980-02-25 1981-08-28 Government Us America Nouveau complexe hydrophile, resistant aux nucleases, d'acide polyriboinosinique-polyribocytidylique, son procede de preparation et son application comme inducteur d'interferon
JPS572220A (en) 1980-06-09 1982-01-07 Toray Ind Inc Production of interferon
US4389395A (en) * 1981-01-09 1983-06-21 Lerner A Martin Low molecular weight complex of polyriboinosinic-polyribocytidylic acid and method of inducing interferon
US4400375A (en) * 1981-11-23 1983-08-23 Eli Lilly And Company Tobramycin-double stranded RNA complex suitable for inducing interferon
ATE61935T1 (de) * 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
US4857315A (en) 1986-09-29 1989-08-15 Mount Sinai Hospital Corporation Compositions containing golgi alpha-mannosidase II inhibitors
JPH01186818A (ja) 1988-01-18 1989-07-26 Yamasa Shoyu Co Ltd ポリリボイノシン酸・ポリリボシチジル酸・ポリ−ｌ−リジン複合体製剤
US5230883A (en) * 1989-05-04 1993-07-27 Wisconsin Alumni Research Foundation Method for localization and treatment of tumors using polylysine complexes
CN1056315C (zh) * 1993-05-31 2000-09-13 林海祥 聚肌胞复合物免疫佐剂及含有该佐剂的疫苗
ATE252894T1 (de) * 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
CA2203843C (en) * 1997-04-28 2013-07-23 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Liposome-encapsulated poly iclc
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
AU2004263037B2 (en) 2003-08-11 2011-02-10 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Novel vaccine containing adjuvant capable of inducing mucosal immunity
AU2005238272A1 (en) * 2004-04-28 2005-11-10 Paradigm Therapeutics Limited Ion channel
KR101203401B1 (ko) * 2005-06-08 2012-11-22 이쉥 바이오파마(싱가포르)피티이 리미티드 폴리이노신산-폴리시티딜산-기초 보조제
US20070166800A1 (en) 2006-01-13 2007-07-19 Haixiang Lin Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
US20070166239A1 (en) 2006-01-13 2007-07-19 Haixiang Lin Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant

Also Published As

Publication number Publication date
MY150706A (en) 2014-02-28
US8303966B2 (en) 2012-11-06
TW200800258A (en) 2008-01-01
AU2006335367B2 (en) 2012-08-30
EP1971402A1 (en) 2008-09-24
EP1971402A4 (en) 2010-07-14
WO2007081287A1 (en) 2007-07-19
IL192746A0 (en) 2009-02-11
CU23810A3 (es) 2012-04-15
NZ570379A (en) 2012-07-27
US20070166800A1 (en) 2007-07-19
RU2008133217A (ru) 2010-02-20
ZA200806339B (en) 2010-03-31
RU2462264C2 (ru) 2012-09-27
US20130115244A1 (en) 2013-05-09
TWI503125B (zh) 2015-10-11
JP2009523721A (ja) 2009-06-25
CN101166559A (zh) 2008-04-23
US20090175902A1 (en) 2009-07-09
BRPI0621181A2 (pt) 2011-11-22
CA2632415A1 (en) 2007-07-19
US20110212123A1 (en) 2011-09-01
AU2006335367A1 (en) 2007-07-19
WO2007081287A9 (en) 2007-12-21
CN101166559B (zh) 2012-08-22
KR20080091106A (ko) 2008-10-09
HK1112863A1 (en) 2008-09-19

Similar Documents

Publication Publication Date Title
BRPI0607840A2 (pt) uso de uma composição imunogência, e de um antìgeno de vzv, vacina ou composição imunogênica, e, kit
MY150706A (en) Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
BRPI0520330A2 (pt) adjuvante a base de ácido polinosìnico-policitidìlico
BRPI1013780B8 (pt) Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
MX2010001054A (es) Composiciones adyuvantes antigenicas y metodos.
MXPA05013973A (es) Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
CO6260103A2 (es) Composiciones que comprenden antigenos neumococidos
CU23819A3 (es) Sustancias inmunogénicas mucosales que comprenden un adyuvante a base de ácido poliinosínico-ácido policitidílico
BRPI1009828A2 (pt) adjuvante de proteína de ligação de fator h meningocócica
CU23759A3 (es) Composiciones inmunogénicas
UY31942A (es) Formulaciones de adyuvante comprendiendo combinaciones de triterpenoides, esteroles, inmunomoduladores, polímeros y estimuladores de th2, procedimientos de preparación, composiciones y aplicaciones.
WO2008100598A3 (en) A method for enhancing t cell response
BRPI0607551A2 (pt) vacinas de combinação de helicobacter e circovìrus porcino e métodos de uso
CO6382137A2 (es) Oligonucleótidos inmunoestimuladores
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
NO20092021L (no) Faste former inneholdende 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluor-fenylamino)-9H-purin-2-ylamino]-cykloheksan-1-ol, sammensetninger derav og anvendelse derav
BRPI0509828A (pt) composição de estimulação da resposta imune compreendendo nanopartìculas com base em éter maleico vinil metil e copolìmero anidrido
BR112023019301A2 (pt) Formulações de vacina de coronavírus
AR068419A1 (es) Cepas de mycoplasma atenuadas vivas
BRPI0508064A (pt) flavivìrus, composição de vacina e molécula de ácido nucléico
BR112016002354A2 (pt) composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit
CL2019000019A1 (es) Anticuerpos con baja inmunogenicidad y uso de los mismos
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
BRPI0608430A2 (pt) composição adjuvante, processo para preparar a mesma e uso da mesma
AR051826A1 (es) Composiciones inmunogenicas de antigenos polipeptidicos de staphylococcus epidermidis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE A DESPACHO 8.6 NA RPI 2163 DE 19/06/2012.

B25D Requested change of name of applicant approved

Owner name: YISHENG BIOPHARMA (SINGAPORE) PTE LTD (SG)

B15K Others concerning applications: alteration of classification

Ipc: A61K 39/00 (2006.01), A61P 31/00 (2006.01), A61K 3

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]